- Home
- AKA vs TARA Comparison
AKA vs TARA Comparison
Compare AKA & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- TARA
- Stock Information
- Founded
- AKA 2018
- TARA N/A
- Country
- AKA United States
- TARA United States
- Employees
- AKA N/A
- TARA N/A
- Industry
- AKA Catalog/Specialty Distribution
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKA Consumer Discretionary
- TARA Health Care
- Exchange
- AKA Nasdaq
- TARA Nasdaq
- Market Cap
- AKA 126.7M
- TARA 126.5M
- IPO Year
- AKA 2021
- TARA N/A
- Fundamental
- Price
- AKA $12.00
- TARA $3.14
- Analyst Decision
- AKA Buy
- TARA Strong Buy
- Analyst Count
- AKA 4
- TARA 7
- Target Price
- AKA $22.50
- TARA $20.67
- AVG Volume (30 Days)
- AKA 8.3K
- TARA 275.9K
- Earning Date
- AKA 08-06-2025
- TARA 08-05-2025
- Dividend Yield
- AKA N/A
- TARA N/A
- EPS Growth
- AKA N/A
- TARA N/A
- EPS
- AKA N/A
- TARA N/A
- Revenue
- AKA $586,514,000.00
- TARA N/A
- Revenue This Year
- AKA $6.60
- TARA N/A
- Revenue Next Year
- AKA $4.14
- TARA N/A
- P/E Ratio
- AKA N/A
- TARA N/A
- Revenue Growth
- AKA 8.09
- TARA N/A
- 52 Week Low
- AKA $7.00
- TARA $1.60
- 52 Week High
- AKA $32.25
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- AKA 48.28
- TARA 43.16
- Support Level
- AKA $12.32
- TARA $3.23
- Resistance Level
- AKA $12.91
- TARA $3.51
- Average True Range (ATR)
- AKA 0.55
- TARA 0.18
- MACD
- AKA -0.15
- TARA 0.03
- Stochastic Oscillator
- AKA 36.97
- TARA 24.49
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).